Press Releases Statement: Inspector General’s Decision To Investigate FDA’s Inappropriately Close Collaboration With Biogen on the Alzheimer’s Disease Drug Aducanumab Is Long Overdue August 4, 2021
Press Releases Letter: Woodcock Must Be Investigated as Part of IG’s Probe Into Aducanumab’s Approval July 13, 2021
Press Releases Statement: Woodcock’s Role in Aducanumab’s Approval Must be Investigated as Part of IG Probe July 9, 2021
Press Releases Letter: Acting FDA Commissioner Woodcock, Other Top Officials Must Resign Following Indefensible Aducanumab Approval June 16, 2021
Press Releases Federal Agencies Must Investigate Serious Regulatory, Ethical Lapses in Reckless Epilepsy Clinical Trial Funded by NIH June 8, 2021
Press Releases Statement: FDA’s Decision to Approve Aducanumab for Alzheimer’s Disease Shows Reckless Disregard for Science, Severely Damages Agency’s Credibility June 7, 2021
Press Releases Statement: FDA Must Reject Tanezumab as a Treatment for Osteoarthritis Due to Unacceptable Dangers, Little to No Benefit March 23, 2021
Press Releases Statement: NIAID’s Statement on AstraZeneca’s Vaccine is Remarkable and Troubling March 23, 2021